Study of Iguratimod in Sjögren's Syndrome
NCT03023592 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2017-01-18
Summary
A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome
Conditions
- Sjogren's Syndrome
Interventions
- DRUG
-
Iguratimod
Iguratimod 25 mg orally twice a day for 24 weeks
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Principal Investigators
-
Yan Zhao, Dr. · Peking Union Medical College Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-02-28
- Primary Completion
- 2018-02-28
- Completion
- 2018-04-30
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Baricitinib in Sjogren's Syndrome
NCT05016297 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
NCT02614716 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome
NCT02691949 ·Status: UNKNOWN ·Phase: PHASE2
-
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
NCT00101829 ·Status: COMPLETED ·Phase: PHASE1
-
New Clinical End-points in Patients With Primary Sjögren's Syndrome
NCT05113004 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
NCT06411639 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525 ·Status: RECRUITING ·Phase: PHASE2
-
Autoimmunity in Retinitis Pigmentosa
NCT00433277 ·Status: UNKNOWN ·Phase: NA
-
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SS-INQ Information Needs Questionnaire in Sjögren's Syndrome
NCT04798911 ·Status: COMPLETED
-
Tolerance and Efficacy of Rituximab in Sjogren's Disease
NCT00740948 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Salivary Biomarkers for Sjögren's Syndrome Detection
NCT01807689 ·Status: COMPLETED
-
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
NCT05789030 ·Status: RECRUITING ·Phase: NA
-
Study of Sirolimus in IgG4-related Disease
NCT05746689 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
NCT00632866 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
NCT02829541 ·Status: COMPLETED ·Phase: PHASE1
-
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
NCT04931160 ·Status: RECRUITING ·Phase: NA
-
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
NCT03247686 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
NCT06144710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1